BioWorld

May 14, 2008

Cash-Strapped Iomai Jumps on $189M Buyout Bid by Intercell

Shares of Iomai Corp. surged more than 117 percent after the firm agreed to be acquired by Austrian vaccines maker Intercell AG in a deal valued at about $189 million. (BioWorld Today) Read More

KAI, BMS Join Forces in $227M Heart Drug Deal

Novacea Slashing Jobs Following Ill-Fated Trial

NewCo News: Making Fossil Fuel Supplies, but Leaving Out the Fossils

Other News To Note

Earnings Roundup

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 3, 2025.

Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B

BioWorld

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1...

ASCO 2025: Verastem has positive cancer data but stock sags

BioWorld

New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was encouraged by the efficacy results. However,...

Pan-cancer proteome atlas reveals new biomarkers and targets

BioWorld Science

An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...